|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Eastern
Cooperative Oncology Group: Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Santos E, Martin-Zanca D, Reddy EP,
Pierotti MA, Della Porta G and Barbacid M: Malignant activation of
a K-ras oncogene in lung carcinoma but not in normal tissue of the
same patient. Science. 223:661–664. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takeuchi K, Soda M, Togashi Y, Suzuki R,
Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, et
al: RET, ROS1 and ALK fusions in lung cancer. Nat Med. 18:378–381.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kohno T, Ichikawa H, Totoki Y, Yasuda K,
Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, et
al: KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 18:375–377.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lipson D, Capelletti M, Yelensky R, Otto
G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T,
Brennan KW, et al: Identification of new ALK and RET gene fusions
from colorectal and lung cancer biopsies. Nat Med. 18:382–384.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shaw AT, Yeap BY, Mino-Kenudson M,
Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S,
McDermott U, et al: Clinical features and outcome of patients with
non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol.
27:4247–4253. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thunnissen E, Bubendorf L, Dietel M,
Elmberger G, Kerr K, Lopez-Rios F, Moch H, Olszewski W, Pauwels P,
Penault-Llorca F and Rossi G: EML4-ALK testing in non-small cell
carcinomas of the lung: A review with recommendations. Virchows
Arch. 461:245–257. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Buettner R, Wolf J and Thomas RK: Lessons
learned from lung cancer genomics: The emerging concept of
individualized diagnostics and treatment. J Clin Oncol.
31:1858–1865. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thun MJ, Hannan LM, Adams-Campbell LL,
Boffetta P, Buring JE, Feskanich D, Flanders WD, Jee SH, Katanoda
K, Kolonel LN, et al: Lung cancer occurrence in never-smokers: An
analysis of 13 cohorts and 22 cancer registry studies. PLoS Med.
5:e1852008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pomerleau CS, Pomerleau OF, Snedecor SM
and Mehringer AM: Defining a never-smoker: Results from the
nonsmokers survey. Addict Behav. 29:1149–1154. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
U.S. Department of Health and Human
Services: The Health Consequences of Smoking-50 Years of Progress:
A Report of the Surgeon General. Office of the Surgeon General
(Rockville, MD). 139–351. 2014.
|
|
18
|
Gazdar AF and Thun MJ: Lung cancer, smoke
exposure, and sex. J Clin Oncol. 25:469–471. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Scagliotti GV, Longo M and Novello S:
Nonsmall cell lung cancer in never smokers. Curr Opin Oncol.
21:99–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kwak EL, Bang YJ, Camidge DR, Shaw AT,
Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Karachaliou N, Mayo C, Costa C, Magrí I,
Gimenez-Capitan A, Molina-Vila MA and Rosell R: KRAS mutations in
lung cancer. Clin Lung Cancer. 14:205–214. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi YH, Lee JK, Kang HJ, Lee TS, Kim HR,
Kim CH, Koh JS, Baek HJ, Lee JC and Na II: Association between age
at diagnosis and the presence of EGFR mutations in female patients
with resected non-small cell lung cancer. J Thorac Oncol.
5:1949–1952. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ueno T, Toyooka S, Suda K, Soh J, Yatabe
Y, Miyoshi S, Matsuo K and Mitsudomi T: Impact of age on epidermal
growth factor receptor mutation in lung cancer. Lung Cancer.
78:207–211. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mitsudomi T: Advances in target therapy
for lung cancer. Jpn J Clin Oncol. 40:101–106. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ,
Yang JJ, Zhou Q, Yang XN, Huang L, Guan JL, et al: Identification
of enriched driver gene alterations in subgroups of non-small cell
lung cancer patients based on histology and smoking status. PLoS
One. 7:e401092012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bos JL: ras oncogenes in human cancer: A
review. Cancer Res. 49:4682–4689. 1989.PubMed/NCBI
|
|
27
|
Thu KL, Vucic EA, Chari R, Zhang W,
Lockwood WW, English JC, Fu R, Wang P, Feng Z, MacAulay CE, et al:
Lung adenocarcinoma of never smokers and smokers harbor
differential regions of genetic alteration and exhibit different
levels of genomic instability. PLoS One. 7:e330032012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mao C, Qiu LX, Liao RY, Du FB, Ding H,
Yang WC, Li J and Chen Q: KRAS mutations and resistance to
EGFR-TKIs treatment in patients with non-small cell lung cancer: A
meta-analysis of 22 studies. Lung Cancer. 69:272–278. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Le Calvez F, Mukeria A, Hunt JD, Kelm O,
Hung RJ, Tanière P, Brennan P, Boffetta P, Zaridze DG and Hainaut
P: TP53 and KRAS mutation load and types in lung cancers in
relation to tobacco smoke: Distinct patterns in never, former, and
current smokers. Cancer Res. 65:5076–5083. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brose MS, Volpe P, Feldman M, Kumar M,
Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, et
al: BRAF and RAS mutations in human lung cancer and melanoma.
Cancer Res. 62:6997–7000. 2002.PubMed/NCBI
|
|
31
|
Cataldo VD, Gibbons DL, Pérez-Soler R and
Quintás-Cardama A: Treatment of non-small-cell lung cancer with
erlotinib or gefitinib. N Engl J Med. 364:947–955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vakiani E and Solit DB: KRAS and BRAF:
Drug targets and predictive biomarkers. J Pathol. 223:219–229.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wan PT, Garnett MJ, Roe SM, Lee S,
Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ,
Barford D and Marais R: Cancer Genome Project: Mechanism of
activation of the RAF-ERK signaling pathway by oncogenic mutations
of B-RAF. Cell. 116:855–867. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rosell R, Bivona TG and Karachaliou N:
Genetics and biomarkers in personalisation of lung cancer
treatment. Lancet. 382:720–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brustugun OT, Khattak AM, Trømborg AK,
Beigi M, Beiske K, Lund-Iversen M and Helland Å: BRAF-mutations in
non-small cell lung cancer. Lung Cancer. 84:36–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Morris SW, Kirstein MN, Valentine MB,
Dittmer KG, Shapiro DN, Saltman DL and Look AT: Fusion of a kinase
gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's
lymphoma. Science. 263:1281–1284. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Palmer RH, Vernersson E, Grabbe C and
Hallberg B: Anaplastic lymphoma kinase: Signalling in development
and disease. Biochem J. 420:345–361. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Coffin CM, Hornick JL and Fletcher CD:
Inflammatory myofibroblastic tumor: Comparison of
clinicopathologic, histologic, and immunohistochemical features
including ALK expression in atypical and aggressive cases. Am J
Surg Pathol. 31:509–520. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen Y, Takita J, Choi YL, Kato M, Ohira
M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, et al:
Oncogenic mutations of ALK kinase in neuroblastoma. Nature.
455:971–974. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Inamura K, Takeuchi K, Togashi Y, Nomura
K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, et
al: EML4-ALK fusion is linked to histological characteristics in a
subset of lung cancers. J Thorac Oncol. 3:13–17. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Takeuchi K, Choi YL, Soda M, Inamura K,
Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, et
al: Multiplex reverse transcription-PCR screening for EML4-ALK
fusion transcripts. Clin Cancer Res. 14:6618–6624. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shinmura K, Kageyama S, Tao H, Bunai T,
Suzuki M, Kamo T, Takamochi K, Suzuki K, Tanahashi M, Niwa H, et
al: EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-,
or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.
Lung Cancer. 61:163–169. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wong DW, Leung EL, So KK, Tam IY, Sihoe
AD, Cheng LC, Ho KK, Au JS, Chung LP and Wong Pik M: University of
Hong Kong Lung Cancer Study Group: The EML4-ALK fusion gene is
involved in various histologic types of lung cancers from
nonsmokers with wild-type EGFR and KRAS. Cancer. 115:1723–1733.
2009. View Article : Google Scholar : PubMed/NCBI
|
